Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Share-based Compensation (2016 - 2025)

Corcept Therapeutics' Share-based Compensation history spans 10 years, with the latest figure at $20.8 million for Q4 2025.

  • For Q4 2025, Share-based Compensation rose 23.65% year-over-year to $20.8 million; the TTM value through Dec 2025 reached $84.5 million, up 37.73%, while the annual FY2025 figure was $84.5 million, 37.73% up from the prior year.
  • Share-based Compensation for Q4 2025 was $20.8 million at Corcept Therapeutics, down from $22.9 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $22.9 million in Q3 2025 and bottomed at $10.1 million in Q1 2021.
  • The 5-year median for Share-based Compensation is $12.4 million (2023), against an average of $14.0 million.
  • The largest annual shift saw Share-based Compensation fell 4.17% in 2022 before it soared 64.77% in 2025.
  • A 5-year view of Share-based Compensation shows it stood at $10.8 million in 2021, then fell by 2.67% to $10.5 million in 2022, then increased by 24.18% to $13.1 million in 2023, then rose by 28.56% to $16.8 million in 2024, then grew by 23.65% to $20.8 million in 2025.
  • Per Business Quant, the three most recent readings for CORT's Share-based Compensation are $20.8 million (Q4 2025), $22.9 million (Q3 2025), and $19.0 million (Q2 2025).